Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
|
16 December 2019 |
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
|
11 December 2019 |
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
|
03 December 2019 |
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
|
29 November 2019 |
AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development
|
07 November 2019 |
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
|
30 October 2019 |
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
|
17 October 2019 |
AstraZeneca divests rights for Losec to Cheplapharm
|
01 October 2019 |
Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial
|
27 September 2019 |
AstraZeneca amends collaboration with Ironwood for Linzess in China
|
19 September 2019 |